Capitalmind Mutual FundEquity Scheme - Flexi Cap Fund1.2 years
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity & equity related instruments across market capitalization i.e. large-cap, mid-cap and small-cap stocks.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 28 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 77% of rolling 1-year windows.
Fits if · Peak-to-trough drawdown has stayed shallower than 15%.
Prefer peers if · Prefer Parag Parikh Flexi Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Fail
1.2 years - thin for judging consistency.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Watch
1.72% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -10.1%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Divyansh Agnani · 0.5 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 39.9% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 10%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY 500 TRI. Capture ratios use common month-end observations through 29 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-10.1%
26 Feb 2026 – 25 Aug 2026
Trough 23 Mar 2026 · recovered in 155 days
-9.2%
7 Jan 2026 – 26 Feb 2026
Trough 1 Feb 2026 · recovered in 25 days
-4.2%
16 Sept 2025 – 13 Oct 2025
Trough 26 Sept 2025 · recovered in 17 days
-3.6%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
18
Vs category
71
Consistency
77
Risk-adjusted
7
Drawdown
75
Mean
50
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 32 holdings · top 10 are 39.9%.
Welspun Corp Ltd
Materials
6.3%
Laurus Labs Ltd
Healthcare
4.4%
Others CBLO
Unspecified
4.2%
Divi's Laboratories Ltd
Healthcare
3.9%
Bank of Maharashtra
Financial
3.8%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
19 Oct 2026
DECISION
Status moved from HEALTHY to MONITOR.
15 Sept 2026
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
PPFAS Mutual Fund
Caveat: Deeper drawdown
Bajaj Finserv Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Bank of India Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Baroda BNP Paribas Mutual Fund
Caveat: Higher volatility · Deeper drawdown
ITI Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Capitalmind Mutual FundEquity Scheme - Flexi Cap Fund1.2 years
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity & equity related instruments across market capitalization i.e. large-cap, mid-cap and small-cap stocks.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 28 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 77% of rolling 1-year windows.
Fits if · Peak-to-trough drawdown has stayed shallower than 15%.
Prefer peers if · Prefer Parag Parikh Flexi Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Fail
1.2 years - thin for judging consistency.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Watch
1.72% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -10.1%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Divyansh Agnani · 0.5 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 39.9% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 10%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
28 Oct 2026 · -2.0% over 1Y
9.9798
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY 500 TRI. Capture ratios use common month-end observations through 29 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
28 Oct 2026
-6.2%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-10.1%
26 Feb 2026 – 25 Aug 2026
Trough 23 Mar 2026 · recovered in 155 days
-9.2%
7 Jan 2026 – 26 Feb 2026
Trough 1 Feb 2026 · recovered in 25 days
-4.2%
16 Sept 2025 – 13 Oct 2025
Trough 26 Sept 2025 · recovered in 17 days
-3.6%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
18
Vs category
71
Consistency
77
Risk-adjusted
7
Drawdown
75
Mean
50
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 32 holdings · top 10 are 39.9%.
Welspun Corp Ltd
Materials
6.3%
Laurus Labs Ltd
Healthcare
4.4%
Others CBLO
Unspecified
4.2%
Divi's Laboratories Ltd
Healthcare
3.9%
Bank of Maharashtra
Financial
3.8%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
19 Oct 2026
DECISION
Status moved from HEALTHY to MONITOR.
15 Sept 2026